Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Analytik Jena Acquires California-Based UVP

By BiotechDaily International staff writers
Posted on 30 Apr 2013
Analytik Jena, AG (Jena, Germany) recently acquired all of the outstanding shares of UVP, LLC (Upland, CA, USA), including its subsidiary, Ultra-Violet Products, Ltd. (Cambridge UK).

UVP is a leading manufacturer of bioimaging systems for applications in proteomics, genomics, animal and plant sciences. The company also develops ultraviolet (UV) products, light sources, and laboratory equipment such as hybridization ovens, transilluminators, crosslinkers, and polymerase chain reaction (PCR) hoods.

The acquisition of UVP allows Analytik Jena to strengthen its presence in the US market and expand its product range. “With the acquisition of UVP, we are significantly expanding our business activities in the Life Science unit and are laying an excellent basis for developing our successful business model in the US and neighboring regions. Here, we are combining efficient sales structures, a well-coordinated product portfolio, and broad technological expertise in the respective core segments. Further extensive synergies are to arise, especially in sales in Europe and Asia. With UVP, Analytik Jena also gains a production plant in the US dollar currency area,” remarked Klaus Berka, CEO of Analytik Jena, AG.

Analytik Jena is a provider of analytic technology, life-science systems for bioanalytic applications, and high-end optical consumer products. With UVP’s incorporation into Analytik Jena’s life-science business unit, many synergies are expected.

According to Leighton Smith, UVP’s president and CEO, “UVP has an opportunity to contribute significantly to the growth and profitability of Analytik Jena’s Life Science business unit. Our combined manufacturing expertise, portfolio of products and distribution channels open up new market opportunities, and begins an exciting new chapter in UVP’s history of providing innovative products and solutions to our customers.”

Related Links:

Analytik Jena
UVP



Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.